Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)

Next Previous
Trial Profile

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCE-IT; REDUCE-IT CABG; REDUCE-IT DIABETES
  • Sponsors Amarin Corporation; Amarin Pharmaceuticals

Most Recent Events

  • 25 Feb 2025 According to an Amarin Corporation media release,, the company announced that Austria's Health Authorities have approved VAZKEPA for national reimbursement to reduce the risk of cardiovascular events and marks the 10th European health authority to recognize the value of our product to reduce cardiovascular risk based on the strong scientific data from our REDUCE-IT study.
  • 16 Dec 2024 According to an Amarin Corporation media release, National Health Service (NHS) of Italy approved VAZKEPA for national reimbursement to reduce cardiovascular risk in eligible high-risk patients, as per publication in the Official Journal of the Italian Republic (i.e. Gazzetta Ufficiale della Repubblica Italiana).
  • 18 Nov 2024 Results presented at the American Heart Association Scientific Sessions 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top